drugset / Trial / NCT01371604
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the safety and antiviral activity of IDX184 in combination with pegylated interferon and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C virus (HCV) infection.
Timeline
- Start
- 2011-07
- Primary completion
- 2013-03
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IDX184 | Other / unclassified | 50 mg | Oral |
| Subject | IDX184 | Other / unclassified | 100 mg | Oral |
| Background | Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly | Unknown | 180 ug | Subcutaneous |
| Background | Ribavirin | Small molecule | 1000 mg | Oral |
| Background | Ribavirin | Small molecule | 1200 mg | Oral |